BioCentury
ARTICLE | Finance

High as a Kite

Why biotech indexes could take a breather in 4Q17

October 6, 2017 11:29 PM UTC

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing to carry the sector through 4Q17.

The consensus view from 21 bankers and buysiders polled by BioCentury is that the public markets are now fairly valuing biotech stocks...